Morganti, Stefania
Jin, Qingchun http://orcid.org/0000-0001-6388-5123
Vincuilla, Julie
Buehler, Ryan
Ryan, Sean
Stokes, Samantha
Parker, Tonia
Mittendorf, Elizabeth A.
King, Tari A.
Weiss, Anna
Partridge, Ann H. http://orcid.org/0000-0002-4722-4824
Bychkovsky, Brittany L. http://orcid.org/0000-0001-7969-0603
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Tayob, Nabihah http://orcid.org/0000-0001-6088-167X
Lin, Nancy U.
Garber, Judy E.
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Lynce, Filipa http://orcid.org/0000-0001-6615-7076
Funding for this research was provided by:
Friends of Dana-Farber Cancer Institute
Italian Association for Cancer Research (AIRC); Gianni Bonadonna Foundation
Article History
Received: 29 June 2023
Accepted: 22 March 2024
First Online: 16 April 2024
Competing interests
: E.A.M. reports compensated service on scientific advisory boards for Astra Zeneca, BioNTech and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers’ honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. T.A.K. reports speaker honoraria and compensated service on scientific Advisory Board of Exact Sciences. A.W. reports compensated service on scientific advisory boards for Merck and Myriad, and institutional research funding from Myriad. G.C. reports consulting fees from Seagen, Roche, Novartis, Lilly, Daiichi Sankyo, Astra Zeneca, Pfizer, Sanofi, Pierre Fabre, and Gilead and fees for non-CME services (e.g., speakers’ bureaus) from Lilly, Pfizer, and Daiichi Sankyo. N.T. reports research funding and consulting from AstraZeneca. N.U.L. reports institutional research support from Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle Genetics (now Pfizer), Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., and Eisai; royalties from UpToDate; and travel support from Olema Pharmaceuticals. J.E.G. reports research funding from Invitae Genetics, Ambry Genetics and Myriad Genetics. S.M.T. reports consulting/advisory role Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA; research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep; and travel support from Eli Lilly, Sanofi, and Gilead. S.M. reports support from AstraZeneca and Menarini/Stemline. F.L. reports consulting/advisory role for AstraZeneca, Pfizer, Merck and Daiichi Sankyo; and institutional research funding from Eisai, Incyte, Genentech, AstraZeneca, CytomX and Gilead Sciences. All other authors report no conflicts of interest.